Jennifer L McQuade1, Gabriel O Ologun2, Reetakshi Arora2, Jennifer A Wargo3. 1. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0430, Houston, 77030, TX, USA. JMcQuade@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX, 77030, USA. 3. Department of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: We review emerging evidence regarding the impact of gut microbes on antitumor immunity, and ongoing efforts to translate this in clinical trials. RECENT FINDINGS: Pre-clinical models and human cohort studies support a role for gut microbes in modulating overall immunity and immunotherapy response, and numerous trials are now underway exploring strategies to modulate gut microbes to enhance responses to cancer therapy. This includes the use of fecal microbiota transplant (FMT), which is being used to treat patients with Clostridium difficile infection among other non-cancer indications. The use of FMT is now being extended to modulate gut microbes in patients being treated with cancer immunotherapy, with the goal of enhancing responses and/or to ameliorate toxicity. However, significant complexities exist with such an approach and will be discussed herein. Data from ongoing studies of FMT in cancer will provide critical insights for optimization of this approach.
PURPOSE OF REVIEW: We review emerging evidence regarding the impact of gut microbes on antitumor immunity, and ongoing efforts to translate this in clinical trials. RECENT FINDINGS: Pre-clinical models and human cohort studies support a role for gut microbes in modulating overall immunity and immunotherapy response, and numerous trials are now underway exploring strategies to modulate gut microbes to enhance responses to cancer therapy. This includes the use of fecal microbiota transplant (FMT), which is being used to treat patients with Clostridium difficileinfection among other non-cancer indications. The use of FMT is now being extended to modulate gut microbes in patients being treated with cancer immunotherapy, with the goal of enhancing responses and/or to ameliorate toxicity. However, significant complexities exist with such an approach and will be discussed herein. Data from ongoing studies of FMT in cancer will provide critical insights for optimization of this approach.
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514
Authors: Karla A Lee; Andrew Maltez Thomas; Laura A Bolte; Johannes R Björk; Laura Kist de Ruijter; Federica Armanini; Francesco Asnicar; Aitor Blanco-Miguez; Ruth Board; Neus Calbet-Llopart; Lisa Derosa; Nathalie Dhomen; Kelly Brooks; Mark Harland; Mark Harries; Emily R Leeming; Paul Lorigan; Paolo Manghi; Richard Marais; Julia Newton-Bishop; Luigi Nezi; Federica Pinto; Miriam Potrony; Susana Puig; Patricio Serra-Bellver; Heather M Shaw; Sabrina Tamburini; Sara Valpione; Amrita Vijay; Levi Waldron; Laurence Zitvogel; Moreno Zolfo; Elisabeth G E de Vries; Paul Nathan; Rudolf S N Fehrmann; Véronique Bataille; Geke A P Hospers; Tim D Spector; Rinse K Weersma; Nicola Segata Journal: Nat Med Date: 2022-02-28 Impact factor: 87.241